Ex vivo dual perfusion of an isolated human placenta cotyledon: Towards protocol standardization and improved inter-centre comparability.


Journal

Placenta
ISSN: 1532-3102
Titre abrégé: Placenta
Pays: Netherlands
ID NLM: 8006349

Informations de publication

Date de publication:
08 2022
Historique:
received: 03 12 2021
revised: 06 04 2022
accepted: 04 05 2022
pubmed: 6 7 2022
medline: 17 8 2022
entrez: 5 7 2022
Statut: ppublish

Résumé

Since the full development of the ex vivo dual perfusion model of the human placenta cotyledon, the technique has provided essential insight into how nutrients, lipids, gases, immunoglobulins, endocrine agents, pharmaceuticals, chemicals, nanoparticles, micro-organisms and parasites might traverse the maternofetal barrier. Additionally, the model has been instrumental in gaining a better understanding of the regulation of vascular tone, endocrinology and metabolism within this organ. The human placenta is unique amongst species in its anatomy and transfer modalities. This orthologous diversity therefore requires an appropriate consideration of placental transfer rates of compounds, particles and micro-organisms specific to humans. Different research centres have adapted this model with a wide variation in perfusion parameters, including in the establishment of perfusion, perfusate composition, gassing regime, cannulation method, flow rates, perfused tissue mass, and also in the application of quality control measures. The requirement to harmonise and standardise perfusion practice between centres is largely driven by the need to obtain consistency in our understanding of placental function, but also in the qualification of the model for acceptance by regulatory agencies in drug and toxicology testing. A pilot study is proposed, aiming to describe how existing inter-centre variation in perfusion methodology affects placental metabolism, protein synthesis, oxygen consumption, the materno-fetal transfer of key molecular markers, and placental structure.

Identifiants

pubmed: 35785693
pii: S0143-4004(22)00234-X
doi: 10.1016/j.placenta.2022.05.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

83-89

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Henning Schneider (H)

Dept. Obstetrics & Gynecology, Inselspital, Bern University Hospital, Switzerland. Electronic address: henning.schneider@hispeed.ch.

Christiane Albrecht (C)

Institute of Biochemistry & Molecular Medicine, University of Bern, Switzerland; Swiss National Centre of Competence in Research (NCCR) TransCure, University of Bern, Switzerland. Electronic address: christiane.albrecht@ibmm.unibe.ch.

Mahmoud S Ahmed (MS)

Departments of Obstetrics and Gynecology and Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, USA. Electronic address: maahmed@utmb.edu.

Michelle Broekhuizen (M)

Division of Neonatology, Department of Pediatrics, Erasmus MC, Rotterdam, the Netherlands; Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands. Electronic address: m.broekhuizen@erasmusmc.nl.

Leonie Aengenheister (L)

Particles-Biology Interactions, Empa, Swiss Federal Laboratories for Materials Science and Technology, St. Gallen, Switzerland. Electronic address: leonie.aengenheister@lih.lu.

Tina Buerki-Thurnherr (T)

Particles-Biology Interactions, Empa, Swiss Federal Laboratories for Materials Science and Technology, St. Gallen, Switzerland. Electronic address: tina.buerki@empa.ch.

A H Jan Danser (AHJ)

Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands. Electronic address: a.danser@erasmusmc.nl.

Sophie Gil (S)

University Paris Cité, Placentech®, Paris, F-75014, France. Electronic address: sophie.gil@u-paris.fr.

Stefan R Hansson (SR)

Lund University, Department of Obstetrics and Gynecology, Institute of Clinical Sciences Lund, Lund University, Lund, Sweden. Electronic address: stefan.hansson@med.lu.se.

Rick Greupink (R)

Department of Pharmacology & Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands. Electronic address: Rick.Greupink@radboudumc.nl.

Rohan M Lewis (RM)

University of Southampton, Faculty of Medicine, UK. Electronic address: Rohan.Lewis@soton.ac.uk.

Udo R Markert (UR)

Department of Obstetrics, Placenta Lab, Jena University Hospital, Jena, Germany. Electronic address: markert@med.uni-jena.de.

Line Mathiesen (L)

Department of Public Health, University of Copenhagen, Faculty of Health Sciences, Copenhagen, Denmark. Electronic address: lima@sund.ku.dk.

Nicola Powles-Glover (N)

AstraZeneca, Regulatory Centre of Excellence, Cambridge, UK. Electronic address: Nicola.PowlesGlover@astrazeneca.com.

Christian Wadsack (C)

Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria. Electronic address: christian.wadsack@medunigraz.at.

Paul Brownbill (P)

Maternal and Fetal Health Research Centre, University of Manchester, UK; Manchester Academic Health Sciences Centre, UK. Electronic address: paul.brownbill@manchester.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH